BioCentury
ARTICLE | Clinical News

Sepracor starts Phase III trials of (S)-oxybutynin

June 20, 2001 7:00 AM UTC

SEPR started a U.S. Phase III trial of its sustained release formulation of (s)-oxybutynin in 850 patients with overactive bladder. (s)-Oxybutynin is a chirally pure form of oxybutynin, the active ing...